(WCH) Wacker Chemie - Overview
Exchange: XETRA •
Country: Germany •
Currency: EUR •
Type: Common Stock •
ISIN: DE000WCH8881
Stock: Silicones, Polymers, Biosolutions, Polysilicon
Total Rating 26
Risk 74
Buy Signal -1.59
| Risk 5d forecast | |
|---|---|
| Volatility | 46.4% |
| Relative Tail Risk | -6.78% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.08 |
| Alpha | -11.26 |
| Character TTM | |
|---|---|
| Beta | 0.218 |
| Beta Downside | 0.786 |
| Drawdowns 3y | |
|---|---|
| Max DD | 56.81% |
| CAGR/Max DD | -0.26 |
EPS (Earnings per Share)
Revenue
Description: WCH Wacker Chemie March 04, 2026
Wacker Chemie AG (WCH) is a German specialty chemicals company founded in 1914. It operates globally through four divisions: Silicones, Polymers, Biosolutions, and Polysilicon.
The Silicones division produces various silicone-based products. The Polymers division supplies binders and additives for construction, paper, paint, coating, and adhesive industries. The Biosolutions division offers biotech and catalog products, including pharmaceutical proteins and food additives. The Polysilicon division manufactures hyperpure polysilicon, a key material in the semiconductor industry and solar energy sector.
To further understand Wacker Chemie AGs market position and financial health, consider exploring its detailed analytics on ValueRay.
Headlines to watch out for
- Polysilicon demand from solar and semiconductor industries
- Silicones division revenue growth from construction and automotive
- Raw material cost fluctuations impact profitability
- Biosolutions expansion in pharmaceutical and food sectors
- Energy prices affect production costs and margins
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -821.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA 6.83 > 1.0 |
| NWC/Revenue: 47.81% < 20% (prev 44.26%; Δ 3.55% < -1%) |
| CFO/TA 0.06 > 3% & CFO 542.6m > Net Income -821.1m |
| Net Debt (1.26b) to EBITDA (396.7m): 3.19 < 3 |
| Current Ratio: 3.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.7m) vs 12m ago -0.57% < -2% |
| Gross Margin: 12.00% > 18% (prev 0.17%; Δ 1.18k% > 0.5%) |
| Asset Turnover: 60.29% > 50% (prev 60.81%; Δ -0.52% > 0%) |
| Interest Coverage Ratio: -0.41 > 6 (EBITDA TTM 396.7m / Interest Expense TTM 260.0m) |
Altman Z'' 3.77
| A: 0.30 (Total Current Assets 3.89b - Total Current Liabilities 1.27b) / Total Assets 8.79b |
| B: 0.36 (Retained Earnings 3.15b / Total Assets 8.79b) |
| C: -0.01 (EBIT TTM -105.4m / Avg Total Assets 9.10b) |
| D: 0.69 (Book Value of Equity 3.49b / Total Liabilities 5.04b) |
| Altman-Z'' Score: 3.77 = AA |
Beneish M -2.79
| DSRI: 1.13 (Receivables 825.2m/764.6m, Revenue 5.49b/5.72b) |
| GMI: 1.44 (GM 12.00% / 17.24%) |
| AQI: 0.87 (AQ_t 0.16 / AQ_t-1 0.19) |
| SGI: 0.96 (Revenue 5.49b / 5.72b) |
| TATA: -0.16 (NI -821.1m - CFO 542.6m) / TA 8.79b) |
| Beneish M-Score: -2.79 (Cap -4..+1) = A |
What is the price of WCH shares?
As of March 19, 2026, the stock is trading at EUR 81.30 with a total of 112,390 shares traded.
Over the past week, the price has changed by +2.39%, over one month by -7.47%, over three months by +9.98% and over the past year by -11.10%.
Over the past week, the price has changed by +2.39%, over one month by -7.47%, over three months by +9.98% and over the past year by -11.10%.
Is WCH a buy, sell or hold?
Wacker Chemie has no consensus analysts rating.
What are the forecasts/targets for the WCH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 72.9 | -10.4% |
| Analysts Target Price | - | - |
WCH Fundamental Data Overview March 18, 2026
Market Cap USD = 4.82b (4.21b EUR * 1.1452 EUR.USD)
P/E Forward = 21.9298
P/S = 0.7672
P/B = 1.0862
P/EG = 5.1721
Revenue TTM = 5.49b EUR
EBIT TTM = -105.4m EUR
EBITDA TTM = 396.7m EUR
Long Term Debt = 1.77b EUR (from longTermDebt, two quarters ago)
Short Term Debt = 161.8m EUR (from shortTermDebt, last quarter)
Debt = 2.37b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.26b EUR (from netDebt column, last quarter)
Enterprise Value = 5.09b EUR (4.21b + Debt 2.37b - CCE 1.48b)
Interest Coverage Ratio = -0.41 (Ebit TTM -105.4m / Interest Expense TTM 260.0m)
EV/FCF = -480.6x (Enterprise Value 5.09b / FCF TTM -10.6m)
FCF Yield = -0.21% (FCF TTM -10.6m / Enterprise Value 5.09b)
FCF Margin = -0.19% (FCF TTM -10.6m / Revenue TTM 5.49b)
Net Margin = -14.97% (Net Income TTM -821.1m / Revenue TTM 5.49b)
Gross Margin = 12.00% ((Revenue TTM 5.49b - Cost of Revenue TTM 4.83b) / Revenue TTM)
Gross Margin QoQ = 11.73% (prev 11.50%)
Tobins Q-Ratio = 0.58 (Enterprise Value 5.09b / Total Assets 8.79b)
Interest Expense / Debt = 5.91% (Interest Expense 140.1m / Debt 2.37b)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -79.0m (EBIT -105.4m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 3.06 (Total Current Assets 3.89b / Total Current Liabilities 1.27b)
Debt / Equity = 0.66 (Debt 2.37b / totalStockholderEquity, last quarter 3.60b)
Debt / EBITDA = 3.19 (Net Debt 1.26b / EBITDA 396.7m)
Debt / FCF = -119.3 (out of range, set to none) (Net Debt 1.26b / FCF TTM -10.6m)
Total Stockholder Equity = 4.21b (last 4 quarters mean from totalStockholderEquity)
RoA = -9.02% (Net Income -821.1m / Total Assets 8.79b)
RoE = -19.52% (Net Income TTM -821.1m / Total Stockholder Equity 4.21b)
RoCE = -1.76% (EBIT -105.4m / Capital Employed (Equity 4.21b + L.T.Debt 1.77b))
RoIC = -1.79% (negative operating profit) (NOPAT -79.0m / Invested Capital 4.41b)
WACC = 5.90% (E(4.21b)/V(6.58b) * Re(6.72%) + D(2.37b)/V(6.58b) * Rd(5.91%) * (1-Tc(0.25)))
Discount Rate = 6.72% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF] Fair Price = unknown (Cash Flow -10.6m)
EPS Correlation: -87.55 | EPS CAGR: -71.34% | SUE: -4.0 | # QB: 0
Revenue Correlation: -76.91 | Revenue CAGR: -12.56% | SUE: -0.53 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.08 | Chg7d=+0.040 | Chg30d=+0.040 | Revisions Net=+1 | Analysts=1
EPS current Year (2026-12-31): EPS=0.06 | Chg7d=-0.757 | Chg30d=-0.757 | Revisions Net=+0 | Growth EPS=+101.0% | Growth Revenue=+1.4%
EPS next Year (2027-12-31): EPS=2.43 | Chg7d=-0.175 | Chg30d=-0.022 | Revisions Net=-1 | Growth EPS=+3948.4% | Growth Revenue=+3.8%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
P/E Forward = 21.9298
P/S = 0.7672
P/B = 1.0862
P/EG = 5.1721
Revenue TTM = 5.49b EUR
EBIT TTM = -105.4m EUR
EBITDA TTM = 396.7m EUR
Long Term Debt = 1.77b EUR (from longTermDebt, two quarters ago)
Short Term Debt = 161.8m EUR (from shortTermDebt, last quarter)
Debt = 2.37b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.26b EUR (from netDebt column, last quarter)
Enterprise Value = 5.09b EUR (4.21b + Debt 2.37b - CCE 1.48b)
Interest Coverage Ratio = -0.41 (Ebit TTM -105.4m / Interest Expense TTM 260.0m)
EV/FCF = -480.6x (Enterprise Value 5.09b / FCF TTM -10.6m)
FCF Yield = -0.21% (FCF TTM -10.6m / Enterprise Value 5.09b)
FCF Margin = -0.19% (FCF TTM -10.6m / Revenue TTM 5.49b)
Net Margin = -14.97% (Net Income TTM -821.1m / Revenue TTM 5.49b)
Gross Margin = 12.00% ((Revenue TTM 5.49b - Cost of Revenue TTM 4.83b) / Revenue TTM)
Gross Margin QoQ = 11.73% (prev 11.50%)
Tobins Q-Ratio = 0.58 (Enterprise Value 5.09b / Total Assets 8.79b)
Interest Expense / Debt = 5.91% (Interest Expense 140.1m / Debt 2.37b)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -79.0m (EBIT -105.4m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 3.06 (Total Current Assets 3.89b / Total Current Liabilities 1.27b)
Debt / Equity = 0.66 (Debt 2.37b / totalStockholderEquity, last quarter 3.60b)
Debt / EBITDA = 3.19 (Net Debt 1.26b / EBITDA 396.7m)
Debt / FCF = -119.3 (out of range, set to none) (Net Debt 1.26b / FCF TTM -10.6m)
Total Stockholder Equity = 4.21b (last 4 quarters mean from totalStockholderEquity)
RoA = -9.02% (Net Income -821.1m / Total Assets 8.79b)
RoE = -19.52% (Net Income TTM -821.1m / Total Stockholder Equity 4.21b)
RoCE = -1.76% (EBIT -105.4m / Capital Employed (Equity 4.21b + L.T.Debt 1.77b))
RoIC = -1.79% (negative operating profit) (NOPAT -79.0m / Invested Capital 4.41b)
WACC = 5.90% (E(4.21b)/V(6.58b) * Re(6.72%) + D(2.37b)/V(6.58b) * Rd(5.91%) * (1-Tc(0.25)))
Discount Rate = 6.72% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF] Fair Price = unknown (Cash Flow -10.6m)
EPS Correlation: -87.55 | EPS CAGR: -71.34% | SUE: -4.0 | # QB: 0
Revenue Correlation: -76.91 | Revenue CAGR: -12.56% | SUE: -0.53 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.08 | Chg7d=+0.040 | Chg30d=+0.040 | Revisions Net=+1 | Analysts=1
EPS current Year (2026-12-31): EPS=0.06 | Chg7d=-0.757 | Chg30d=-0.757 | Revisions Net=+0 | Growth EPS=+101.0% | Growth Revenue=+1.4%
EPS next Year (2027-12-31): EPS=2.43 | Chg7d=-0.175 | Chg30d=-0.022 | Revisions Net=-1 | Growth EPS=+3948.4% | Growth Revenue=+3.8%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)